ArticleNature medicine2023
A spinal cord neuroprosthesis for locomotor deficits due to Parkinson's disease.
Registry-linked trialOpen access · greenAbstract readCase Reports
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06295614 (Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
17.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- A Pragmatic Review on Spinal Cord Stimulation Therapy for Parkinson's Disease Gait Related Disorders: Gaps and Controversies.Movement disorders clinical practice · 2024Pooled it
- Electromyography (EMG)-triggered transcutaneous spinal cord and hip stimulation for gait rehabilitation in persons with chronic stroke: a randomized, controlled trial.Journal of neuroengineering and rehabilitation · 2025Trial
- First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy.Nature medicine · 2025Trial
- Neural Network Connection Characteristics Between Motor Cortex and Spinal Cord During Rat Bipedal Walking.CNS neuroscience & therapeutics · 2026Article
- Activity-dependent adaptive deep brain stimulation improves gait in Parkinson's disease.Nature medicine · 2026Article
- Predict neuromuscular performance in human epidural electrical stimulation: phase 1 trial interim results.Communications medicine · 2026Article
- Advancing neuroengineering with Neuromorphic Twins.Nature communications · 2026Review
- Article
- Brain-computer interface commercialization.Journal of neuroengineering and rehabilitation · 2026Article
- A spinal network of proprioceptive reflexes can produce a variety of bipedal gaits.Communications biology · 2025Article
- Subthalamic Electrophysiological Mapping of Gait Initiation Dynamics and Freezing in Parkinson's Disease.Annals of neurology · 2025Article
- DeviceAgent: An autonomous multimodal AI agent for flexible bioelectronics.bioRxiv : the preprint server for biology · 2025Article
- Second harmonic generation for brain imaging: pathology-related studies.Biophysical reviews · 2025Article
- Capturing the Electrical Activity of all Cortical Neurons: Are Solutions Within Reach?Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Regional specialization of movement encoding across the primate sensorimotor cortex.Nature communications · 2025Article
- Multifunctional bioelectronics for brain-body circuits.Nature reviews bioengineering · 2025Article
- Neural network-assisted personalized handwriting analysis for Parkinson's disease diagnostics.Nature chemical engineering · 2025Article
- Implantable Self-Powered Systems for Electrical Stimulation Medical Devices.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Management of freezing of gait - mechanism-based practical recommendations.Nature reviews. Neurology · 2025Review
- Micro-Coil Neuromodulation at Single-Cell and Circuit Levels for Inhibiting Natural Neuroactivity, Neutralizing Electric Neural Excitation, and Suppressing Seizures.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
- Commented on by
Authors and funding
57 authors at 14 institutions in 6 countries.
Tomislav Milekovic *NeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.ORCID 0000-0001-6769-6506
Eduardo Martin Moraud *Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-6148-7065
Nicolo Macellari *NeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Charlotte Moerman *Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0009-0009-0009-2957
Flavio Raschellà *NeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Shiqi Sun *NeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.ORCID 0009-0009-7257-7996
Matthew G Perich *Department of Fundamental Neuroscience, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID 0000-0001-9800-2386
Camille VaresconNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Robin DemesmaekerNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.ORCID 0000-0003-0856-0929
Alice BruelInstitute of Bioengineering, School of Engineering, EPFL, Lausanne, Switzerland.
Léa N Bole-FeysotNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Giuseppe SchiavoneNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.ORCID 0000-0001-7121-9825
Elvira PirondiniDepartment of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Cheng YunLongMotac Neuroscience, UK-M15 6WE, Manchester, UK.
Li HaoMotac Neuroscience, UK-M15 6WE, Manchester, UK.
Andrea GalvezNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Sergio Daniel Hernandez-CharpakNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.ORCID 0000-0003-0477-8138
Gregory DumontNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Jimmy RavierNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Camille G Le Goff-MignardotNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Jean-Baptiste MignardotNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Gaia CarparelliNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Cathal HarteNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Nicolas HankovNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Viviana AureliNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Anne WatrinONWARD Medical, Lausanne, Switzerland.
Hendrik LambertONWARD Medical, Lausanne, Switzerland.
David BortonNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.ORCID 0000-0003-0710-3005
Jean LaurensNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Isabelle VollenweiderNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Simon BorgognonNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.ORCID 0000-0002-4577-6553
François BourreUniversité de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
Michel GoillandeauUniversité de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
Wai Kin D KoMotac Neuroscience, UK-M15 6WE, Manchester, UK.
Laurent PetitUniversité de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.ORCID 0000-0003-2499-5367
Qin LiMotac Neuroscience, UK-M15 6WE, Manchester, UK.
Rik BuschmanMedtronic, Minneapolis, USA.
Nicholas BuseMedtronic, Minneapolis, USA.
Maria YaroshinskyDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Jean-Baptiste LedouxDepartment of Diagnostic and Interventional Radiology, CHUV/UNIL, Lausanne, Switzerland.ORCID 0000-0003-0447-5073
Fabio BecceDepartment of Diagnostic and Interventional Radiology, CHUV/UNIL, Lausanne, Switzerland.ORCID 0000-0001-8444-8504
Mayté Castro JimenezDepartment of Neurology, CHUV/UNIL, Lausanne, Switzerland.ORCID 0000-0003-4165-4804
Julien F BallyDepartment of Neurology, CHUV/UNIL, Lausanne, Switzerland.ORCID 0000-0002-0970-8844
Timothy DenisonOxford University, Oxford, UK.
Dominique GuehlUniversité de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
Auke IjspeertInstitute of Bioengineering, School of Engineering, EPFL, Lausanne, Switzerland.ORCID 0000-0003-1417-9980
Marco CapogrossoNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.ORCID 0000-0002-0975-316X
Jordan W SquairNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
Leonie AsbothNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.ORCID 0000-0003-2414-9574
Philip A StarrDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2733-4003
Doris D WangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Stéphanie P LacourNeuroX Institute, School of Bioengineering, EPFL, Lausanne, Switzerland.ORCID 0000-0001-9075-4022
Silvestro MiceraNeuroX Institute, School of Bioengineering, EPFL, Lausanne, Switzerland.ORCID 0000-0003-4396-8217
Chuan QinChina Academy of Medical Sciences, Beijing, China.
Jocelyne BlochNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland. jocelyne.bloch@chuv.ch.ORCID 0000-0002-6405-1590
Erwan BezardMotac Neuroscience, UK-M15 6WE, Manchester, UK. erwan.bezard@u-bordeaux.fr.ORCID 0000-0002-0410-4638
G CourtineNeuroX Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland. gregoire.courtine@epfl.ch.ORCID 0000-0002-5744-4142
Hôpital Orthopédique de la Suisse Romande · CHCentre National de la Recherche Scientifique · FRChinese Academy of Medical Sciences & Peking Union Medical College · CNUniversity Hospital of Lausanne · CHÉcole Polytechnique Fédérale de Lausanne · CHUniversity of California, San Francisco · USBioengineering (Switzerland) · CHMedtronic (United States) · USUniversity of Geneva · CHUniversity of Pittsburgh · USAllen Institute for Brain Science · USBaylor College of Medicine · USScuola Superiore Sant'Anna · ITUniversity of Oxford · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with late-stage Parkinson's disease (PD) often suffer from debilitating locomotor deficits that are resistant to currently available therapies. To alleviate these deficits, we developed a neuroprosthesis operating in closed loop that targets the dorsal root entry zones innervating lumbosacral segments to reproduce the natural spatiotemporal activation of the lumbosacral spinal cord during walking. We first developed this neuroprosthesis in a non-human primate model that replicates locomotor deficits due to PD. This neuroprosthesis not only alleviated locomotor deficits but also restored skilled walking in this model. We then implanted the neuroprosthesis in a 62-year-old male with a 30-year history of PD who presented with severe gait impairments and frequent falls that were medically refractory to currently available therapies. We found that the neuroprosthesis interacted synergistically with deep brain stimulation of the subthalamic nucleus and dopaminergic replacement therapies to alleviate asymmetry and promote longer steps, improve balance and reduce freezing of gait. This neuroprosthesis opens new perspectives to reduce the severity of locomotor deficits in people with PD.
Indexed as
Deep Brain StimulationGait Disorders, NeurologicParkinson DiseaseAnimalsGaitHumansMaleSpinal Cord
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06295614ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.